Can WeightWatchers Regain its Mojo after Oprah Steps Down?

Oprah Winfrey weight watchers

Key Points

  • WeightWatchers stock hit all-time lows after its Q4 2023 earnings report, missing consensus EPS estimates by $1.00 and Oprah Winfrey leaving the Board of Directors.
  • Oprah will also be donating her financial stake in WW to the National Museum of African American History and Culture.
  • WeightWatchers expects to return to YoY growth in subscription revenues in the second half of 2024.
  • 5 stocks we like better than WW International

WW International Inc. NASDAQ: WW (WeightWatchers) has had a disastrous 2024, with its shares collapsing 66.7% year-to-date (YTD). The company made a praiseworthy strategic pivot in 2023, acquiring Sequence Inc. to enter into the GLP-1 clinical weight loss space, gaining the ability to prescribe medications like Novo Nordisk A/V NYSE: NVO owned Ozempic and Wegovy and Eli Lilly& Co. NYSE: LLY GLP-1 agonists like Mounjaro and Zepbound. The foresightful move complemented its flailing WeightWatchers business.

WeightWatchers Shares Surge and Slide

Shares rocketed towards Goldman Sach's $13 price target, which was raised from $3.80. Incidentally, Weight Watchers achieved the target price, hitting $13.31 in October 2023 before plunging to all-time lows of $2.79 after its underwhelming Q4 2023 earnings release. Additionally, its famed director, Oprah Winfrey, who lost over 60 pounds on GLP-1 meds, opted not to seek reelection to its Board of Directors. Investors are left to ponder if Weightwatchers will ever regain its mojo. 

Leading the GLP-1 Platform Trend

Weight Watchers was one of the first platforms to jump on the GLP-1 weight loss trend, which was embraced by telehealth platforms like Teladoc Health Inc. NYSE: TDOC, LifeMD Inc. NASDAQ: LFMD  and Hims & Hers Inc. NYSE: HIMS in the medical sector.

The WeightWatchers Turnaround Loses Shape

On Feb. 28, 2024, Weightwatchers reported a fourth-quarter 2023 GAAP EPS loss of $1.11, missing consensus estimates for a loss of 11 cents by $1.00. Revenues continued to fall 7.6% YoY to $205.96 million versus $206.91 million consensus estimates. Subscribers at the end of the period rose 7.1% to $3.8 million, with 67,000 end-of-period clinical subscribers. Gross margins were 60.4% and 61.4% adjusted, excluding the net impact of restricting charges. Operating loss was $6 million.

For 2023, WeightWatchers ended the year with 67,000 clinical subscribers, which is up 47% sequentially and 3X when the acquisition of Sequence Inc. was announced in 2023. The combination of behavioral and medical weight health solutions is the new integrated approach to the member experience.

Weight watchers building

Downside Guidance for WeightWatchers Stock 

WeightWatchers issued downside guidance for the full year 2024 with revenues of $830 million to $860 million versus $924.03 consensus estimates. The guidance reflects a $55 million YoY headwind from the decision to wind down its low-margin consumer products business. The company's reporting segments will change in 2024, reporting as one segment based on total revenues from North America and internationally.


Oprah Walks Away from WeightWatchers

Oprah Winfrey has been on the WeightWatchers Board of Directors since 2015. Her presence was a ringing endorsement for the brand. Oprah's weight loss of over 60 pounds using GLP-1 treatments further helped the brand, especially during its strategic pivot to focusing on GLP-1 drug prescriptions. However, Oprah stepping down from the Board and donating her shares to the National Museum of African American History and Culture insinuates the loss of her endorsement of the brand. This is what the stock reflects as shares tumbled to their lowest levels ever. It also reveals that the shares had a very real Oprah halo effect that was able to put in a floor, which appears to be gone now.

WeightWatchers CEO comments

WW International CEO Sima Sistani noted that the restructuring also recalibrated their marketing spend. They recalibrated the bulk of their spending to Q3 from Q1, when traditionally 40% of annual sign-ups occurred in the first quarter. They will take the same approach in 2024.

Sistani commented, “We are on track to deliver growth in total subscribers in 2024, expecting to end the year with subscribers in the range of 3.8 million to 4.0 million, including between 140 thousand and 160 thousand subscribers to our new WeightWatchers Clinic.”

WW International analyst ratings and price targets are at MarketBeat. WW International peers and competitor stocks can be found with the MarketBeat stock screener.

 

Daily Descending Triangle

The daily candlestick chart for WW illustrates a descending triangle pattern. The descending upper trendline formed at $3.92 on Feb. 28, 2024, capping bounce attempts at lower highs. The flat-bottom lower trendline sits at the $2.79 low. The daily relative strength index (RSI) has been flat near the 40-band since its earnings release. Pullback support levels are at $2.79, $2.42, $2.04 and $1.58.

Should you invest $1,000 in WW International right now?

Before you consider WW International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and WW International wasn't on the list.

While WW International currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
WW International (WW)
2.5149 of 5 stars
$1.75+10.1%N/A-1.09Hold$9.01
Teladoc Health (TDOC)
2.9939 of 5 stars
$13.01-2.4%N/A-9.23Hold$19.67
Hims & Hers Health (HIMS)
3.4525 of 5 stars
$12.50+1.9%N/A-113.64Moderate Buy$14.85
Eli Lilly and Company (LLY)
4.8129 of 5 stars
$733.51+1.2%0.71%126.47Moderate Buy$728.05
Novo Nordisk A/S (NVO)
2.439 of 5 stars
$126.86+0.9%1.05%46.90Moderate Buy$133.60
Hims & Hers Health (HIMS)
3.4525 of 5 stars
$12.50+1.9%N/A-113.64Moderate Buy$14.85
LifeMD (LFMD)
0.5133 of 5 stars
$11.95+10.4%N/A-17.07Buy$10.40
Compare These Stocks  Add These Stocks to My Watchlist 

Jea Yu

About Jea Yu

  • JeaYu21@gmail.com

Contributing Author

Trading Strategies

Experience

Jea Yu has been a contributing writer for MarketBeat since 2018.

Areas of Expertise

Equities, options, ETFs and futures; fundamental, qualitative, quantitative and technical analysis and pattern identification; active and swing trading; trading systems and methodology development

Education

Bachelor of Arts, University of Maryland, College Park

Past Experience

U.S. equity markets trader, writer and analyst for over 25 years. Published four books by publishers McGraw-Hill, John Wiley & Sons, Marketplace Books and Bloomberg Press. Speaker at various expos and seminars and has been quoted and featured in USA Today, The Wall Street Journal, Traders Magazine, The Financial Times and various trade publications, including Stocks & Commodities, Active Trader and Online Investor.


Featured Articles and Offers

7 Must-Buy Stocks Under $20

7 Must-Buy Stocks Under $20

In this video, we highlight seven stocks under $20 that are worth a closer look.

Search Headlines: